QPlus Pediatric Reference Interval
NCT05645133 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 93
Last updated 2023-06-15
Summary
Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals.
Conditions
- Pediatric ALL
- Healthy
Interventions
- DEVICE
-
Diagnostic Test
Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
Sponsors & Collaborators
-
HemoSonics LLC
lead INDUSTRY
Principal Investigators
-
Christopher Tirotta, MD · Nicklaus Childrens
Eligibility
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-02-27
- Primary Completion
- 2023-06-01
- Completion
- 2023-06-10
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
NCT04759131 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
NCT01230021 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
NCT01333111 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
NCT01253811 ·Status: COMPLETED ·Phase: PHASE3
-
Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography
NCT03002480 ·Status: WITHDRAWN ·Phase: NA
-
A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan
NCT02670213 ·Status: COMPLETED
-
Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis
NCT02263066 ·Status: COMPLETED
-
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
NCT00189982 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
NCT01810666 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
NCT05993533 ·Status: UNKNOWN
-
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
NCT01731600 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
NCT05145127 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
NCT05493631 ·Status: COMPLETED ·Phase: PHASE1
-
Preventing Inhibitor Recurrence Indefinitely
NCT04621916 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients
NCT02727647 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development
NCT01445197 ·Status: TERMINATED ·Phase: PHASE3
-
Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia
NCT02585635 ·Status: COMPLETED
-
An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A
NCT07088458 ·Status: NOT_YET_RECRUITING
-
A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients
NCT03855696 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
NCT06125756 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
NCT00717626 ·Status: COMPLETED ·Phase: PHASE2
-
Survey of Inhibitors in Plasma-Product Exposed Toddlers
NCT01064284 ·Status: COMPLETED ·Phase: PHASE4
-
Improved Factor VIII Inhibitor Evaluation
NCT02726139 ·Status: WITHDRAWN
-
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
NCT00056589 ·Status: COMPLETED ·Phase: PHASE1
-
Age-dependency of Thrombin Generation Using a New Standardized Assay
NCT03007108 ·Status: COMPLETED ·Phase: NA